<SEC-DOCUMENT>0000318154-23-000061.txt : 20231031
<SEC-HEADER>0000318154-23-000061.hdr.sgml : 20231031
<ACCEPTANCE-DATETIME>20231031071517
ACCESSION NUMBER:		0000318154-23-000061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231031
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231031
DATE AS OF CHANGE:		20231031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		231362271

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>amgn-20231031.htm
<DESCRIPTION>AMGN-2023.9.30 8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:adc26e5c-240e-4a1e-ac94-a7cdfbd97ce7,g:9497942b-b8bf-4481-98ae-facda9fa8df2,d:404e194288c6417a8de188d745944de3--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:amgn="http://www.amgen.com/20231031" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20231031</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20231031.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i404e194288c6417a8de188d745944de3_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 OR 15(d) of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;-</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Amgen Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37702</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">91320-1799</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">805</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">447-1000</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">2.000% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i404e194288c6417a8de188d745944de3_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-26">October&#160;31, 2023</ix:nonNumeric>, the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2023, and its unaudited financial position as of September 30, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, non-GAAP other (expense) income, net, non-GAAP interest expense, net, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development (R&amp;D) expenses and non-GAAP selling, general and administrative expenses. Reconciliations for such non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the press release. The Company included Free Cash Flow (FCF), which is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that this presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. The Company uses non-GAAP financial measures in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the costs and other items excluded from the most directly comparable GAAP financial measures to calculate non-GAAP financial measures:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Acquisition-related expenses: Acquisition-related charges are primarily associated with intangible assets acquired in connection with business acquisitions. Such charges include amortization of developed-product-technology rights, licensing rights, R&amp;D technology rights, and marketing-related rights, as well as impairments of in-process R&amp;D assets. Charges for purchased intangible assets are significantly impacted by the timing and magnitude of the Company&#8217;s acquisitions and potential product approvals as they relate to in-process R&amp;D projects acquired. Accordingly, these charges may vary in amount from period to period. The Company excludes these charges for purposes of calculating the non-GAAP financial measures presented to facilitate a more meaningful evaluation of the Company&#8217;s current operating performance and comparisons to past operating performance. The Company believes that excluding the noncash charges related to those intangible assets acquired in business acquisitions treats those assets as if the Company had developed them internally in the past and, thus, provides a supplemental measure of profitability in which the Company&#8217;s acquired intellectual property is treated in a comparable manner to its internally-developed-intellectual property.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Net charges pursuant to the Company&#8217;s restructuring and costs savings initiatives: Costs from restructuring and cost savings initiatives are primarily related to facilities charges, including asset impairments and accelerated depreciation, and severance and benefits for employees terminated pursuant to our transformation and process improvement efforts. Costs from such initiatives are inconsistent in amount and are significantly impacted by the timing and nature of these events. Therefore, although the Company may incur these types of expenses in the future, it believes that eliminating these charges for purposes of calculating the non-GAAP financial measures provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Other items: The Company adjusts GAAP financial results for certain income and expenses (or gains and losses). These adjustments include (1) certain items from investment transactions, including (i) certain gains and losses on our investments in equity securities and (ii) amortization from the basis difference that arose in prior periods from certain equity method investments, recorded to other income and expense; (2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the impact of nonstrategic divestitures, which includes cumulative foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (3) certain items associated with judgments and/or settlements for legal proceedings discussed in our filings; and (4) (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit agreement and term loan credit agreement, incurred prior to the closing of our acquisition of Horizon Therapeutics plc. The Company excludes these items for the purpose of calculating the non-GAAP financial measures presented because the Company believes these items are outside the ordinary course of business. The Company believes eliminating these items provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The tax effect of the adjustments between GAAP and non-GAAP results take into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain gains and losses on our investments in equity securities, whereas the tax impact of other adjustments, including expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The press release also contains a discussion of the additional purposes for which the Company&#8217;s management uses these non-GAAP financial measures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information and the information contained in the press release shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i404e194288c6417a8de188d745944de3_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-2023930earningsrelease.htm">Press Release dated October 31, 2023</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i404e194288c6417a8de188d745944de3_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-27">October 31, 2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>amgn-2023930earningsrelease.htm
<DESCRIPTION>AMGN-2023.9.30 EARNINGS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if4b5ec9552554732b4cde51e3fe96820_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.864%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><img alt="amgenlogoa.jpg" src="amgenlogoa.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:100%">News Release</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:100%">One Amgen Center Drive<br>Thousand Oaks, CA  91320-1799<br>Telephone 805-447-1000<br>www.amgen.com</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="if4b5ec9552554732b4cde51e3fe96820_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:16pt;font-weight:700;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THOUSAND OAKS, Calif. (October&#160;31, 2023) - Amgen (NASDAQ&#58;AMGN) today announced financial results for the third quarter of 2023</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#34;We are excited about our pipeline progress and our operating performance in the third quarter,&#34; said Robert A. Bradway, chairman and chief executive officer. &#34;With the completion of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio.&#34;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key results include&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales. Produ</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ct sales growth was driven by 11% volume growth, partially offset by 3% lower net selling price and 3% unfavorable changes to estimated sales deductions. </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Volume growth of 11% included double-digit volume growth from</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (blinatumomab), EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (romosozumab-aqqg), Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (evolocumab) and Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (romiplostim).</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">U.S. volume grew 11% and ex-U.S. volume grew 12%, including 27% volume growth in the Asia Pacific region.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">GAAP earnings per share (EPS) decreased 19% from $3.98 to $3.22, driven by a net impairment charge in Q3 2023 of approximately $650&#160;million following a decision to discontinue development of AMG 340, partially offset by increased revenues.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">GAAP operating income decreased from $2.7 billion to $2.0 billion, and GAAP operating margin decreased 11.7 percentage points to 30.9%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Non-GAAP EPS increased 6% from $4.70 to $4.96, driven by increased revenues, partially offset by higher operating expenses.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Non-GAAP operating income increased from $3.3 billion to $3.4 billion, and non-GAAP operating margin decreased 0.5 percentage points to 52.0%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Company generated $2.5 billion of free cash flow for the third quarter of 2023 versus $2.8 billion in the third quarter of 2022.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">References in this release to &#8220;non-GAAP&#8221; measures, measures presented &#8220;on a non-GAAP basis&#8221; and &#8220;free cash flow&#8221; (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> The accounting impact of this acquisition and the results of operations for Horizon Therapeutics plc will be included in our consolidated financial statements beginning in the fourth quarter of 2023.</font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_7"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 2</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Performance</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total product sales increased 5% for the third quarte</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">r of 2023 versus the third quarter of 2022. Unit volumes grew 11%, partially offset by 3% lower net selling price and 3% unfavorable changes to estimated sales deductions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">General Medicine</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 31% year-over-year for the third quarter, driven by 44% volume growth, partially offset by lower net selling price. In the U.S., sales grew 29%, driven by 45% volume growth, partially offset by lower net selling price resulting from higher rebates to support and expand access for patients. Outside the U.S., sales grew 34%, driven by 43% volume growth, partially offset by lower net selling price. Repatha remains the global proprotein convertase subtilisin&#47;kexin type 9 (PCSK9) segment leader, with over 2 million patients treated since launch. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 14% year-over-year for the third quarter, primarily driven by 7% volume growth and higher net selling price. We are on track to treat over 7 million patients with Prolia in 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 53% year-over-year to a record $307 million for the third quarter, driven by strong volume growth. U.S. volumes grew 41% year-over-year and volumes outside the U.S. grew 63%.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Aimovig</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (erenumab-aooe) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 12% year-over-year for the third quarter, driven by lower net selling price, partially offset by favorable changes to estimated sales deductions. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inflammation</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (tezepelumab-ekko) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generated $161 million of sales in the third quarter. Quarter-over-quarter sales increased 21%, driven by 18% volume growth that benefited from the pre-filled, single-use pen, which was approved for self-administration by the U.S. Food and Drug Administration (FDA) in the first quarter. Healthcare providers are increasingly recognizing TEZSPIRE&#8217;s unique, differentiated profile and its broad potential to treat the 2.5 million patients worldwide with severe asthma who are uncontrolled, without any phenotypic or biomarker limitation.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (avacopan)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $37 million of sales in the third quarter. Quarter-over-quarter sales increased 23%, driven by volume growth. U.S. volumes grew 18% quarter-over-quarter. In the U.S., approximately 2,300 patients have now been treated with TAVNEOS.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (apremilast) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 10% year-over-year for the third quarter, driven by lower net selling price, unfavorable changes to estimated sales deductions and lower inventory levels, partially offset by 1% volume growth. In the U.S., net selling price declined, driven by higher rebates to support and expand access for commercial and Medicare Part D patients. Otezla demand in the quarter continued to be impacted by free drug programs for newly launched competition. For the remainder of 2023, we expect demand to be affected by these free drug programs.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 3</font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect future growth for Otezla to be driven by its established efficacy and safety profile, strong payer coverage with limited prior authorization requirements and ease of administration. Otezla remains the only approved oral systemic therapy with a broad indication and is well-positioned to help the 1.5 million U.S. patients with mild-to-moderate psoriasis who cannot be optimally addressed by a topical and can benefit from a systemic treatment like Otezla.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (etanercept) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 6% year-over-year for the third quarter, primarily driven by an 8% decline from unfavorable changes to estimated sales deductions, resulting from a $47 million favorable adjustment in the third quarter of 2022 compared to a $37 million unfavorable adjustment in this quarter. Year-over-year volume increased 1% in the third quarter, driven by an increase in new patients starting treatment as a result of improved payer coverage. For the remainder of 2023, we expect this improved coverage will lead to growth in new patients and declining net selling price. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;AMGEVITA&#8482; (adalimumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 30% year-over-year for the third quarter, driven by 53% volume growth, partially offset by lower net selling price. Ex-U.S. sales increased 10% year-over-year, driven by 22% volume growth, partially offset by lower net selling price. U.S. sales increased 21% quarter-over-quarter, driven by 41% volume growth, partially offset by lower inventory levels. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Hematology-Oncology</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 55% year-over-year to a record $220 million for the third quarter, driven by 56% volume growth, supported by broad prescribing for patients with B-cell precursor acute lymphoblastic leukemia.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (panitumumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 2% year-over-year for the third quarter to a record $252 million, driven by higher net selling price and 4% volume growth, partially offset by unfavorable foreign exchange impact. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (carfilzomib)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 10% year-over-year for the third quarter, primarily driven by 8% volume growth. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;LUMYKRAS&#8482; (sotorasib)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $52 million of sales for the third quarter. Year-over-year sales decreased 31% for the third quarter, primarily driven by unfavorable changes to estimated sales deductions related to ongoing reimbursement negotiations in France.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 5% year-over-year for the third quarter, driven by higher net selling price. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 45% year-over-year for the third quarter, driven by 43% volume growth resulting from a $142 million order from the U.S. government.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (bevacizumab-awwb) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 2% year-over-year for the third quarter, driven by 17% volume growth and favorable changes to estimated sales deductions, partially offset by lower net selling price. The published third quarter Average Selling Price (ASP) for MVASI in the U.S. declined 19% year-over-year and 1% quarter-over-quarter. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 4</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Going forward, we expect continued net selling price erosion driven by increased competition.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">KANJINTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (trastuzumab-anns) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 72% year-over-year for the third quarter, driven by lower net selling price, unfavorable changes to estimated sales deductions and volume declines. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Established Products</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Total sales of our established products, which include </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (epoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (darbepoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (etelcalcetide) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (pegfilgrastim)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, decreased 30% year-over-year for the third quarter, driven by lower net selling price and volume declines. In the aggregate, we expect the year-over-year net selling price and volume erosion for this portfolio of products to continue.</font></div><div id="if4b5ec9552554732b4cde51e3fe96820_10"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Detail by Product and Geographic Region</font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;AMGEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50%)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,691&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Change in excess of 100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="33" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**Consists of AVSOLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, RIABNI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Corlanor</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, NEUPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, IMLYGIC</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Sensipar</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;Mimpara</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and BEKEMV</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as well as sales in prior periods of our divested Bergamo and GENSENTA subsidiaries.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM &#61; not meaningful</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 5</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expense, Operating Margin and Tax Rate Analysis</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a GAAP basis&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 22%. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> margin increased 2.1 percentage points, primarily driven by higher profit share, higher amortization expense from acquisition-related assets and changes in product mix. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research &#38; Development (R&#38;D) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses decreased 3%, as lower spend in research and early pipeline was partially offset by higher spend in later-stage clinical programs and marketed products. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General &#38; Administrative (SG&#38;A)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 5%, primarily driven by higher general and administrative expenses, including higher acquisition-related expenses. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> operating expenses consisted of a net impairment charge for AMG 340.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 11.7 percentage points to 30.9%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> increased 0.7 percentage points, primarily driven by the 2022 Puerto Rico tax law change that replaced the excise tax with an income tax beginning in 2023, partially offset by net favorable items and earnings mix, including the tax benefit from the net impairment charge for AMG 340.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a non-GAAP basis&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 4%. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> margin increased 1.3 percentage points, primarily driven by higher profit share and changes in product mix. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses decreased 2%, as lower spend in research and early pipeline was partially offset by higher spend in later-stage clinical programs and marketed products. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SG&#38;A</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 1%.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 0.5 percentage points in the third quarter to 52.0%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> increased 3.2 percentage points, primarily due to the 2022 Puerto Rico tax law change that replaced the excise tax with an income tax beginning in 2023 and earnings mix.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 6</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3) pts.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General &#38; Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8) pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,882</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,992</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,500</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,375</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4%</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Margin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating income as % of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7 pts. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.9</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2 pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pts&#58; percentage points</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* change in excess of 100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM &#61; not meaningful</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow and Balance Sheet</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Company generated $2.5 billion of free cash flow in the third quarter of 2023 versus $2.8 billion in the third quarter of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Company&#8217;s third quarter 2023 dividend of $2.13 per share was declared on August&#160;1, 2023, and was paid on September&#160;8, 2023, to all stockholders of record as of August&#160;18, 2023, representing a 10% increase from 2022. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Cash and investments totaled $34.7 billion and debt outstanding totaled $60.5 billion as of September 30, 2023.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:54.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions, except shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Expenditures</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends Paid</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchases</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Diluted Shares (millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:54.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9&#47;30&#47;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12&#47;31&#47;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YTD &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 7</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Guidance</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the full year 2023, the Company now expects&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Total revenues</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $28.0&#160;billion to $28.4&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $11.23 to $12.73, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 14.0% to 15.5%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">non-GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $18.20 to $18.80, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 16.5% to 17.0%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Capital expenditures</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be approximately $950&#160;million.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Share repurchases</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> not to exceed $500&#160;million.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div id="if4b5ec9552554732b4cde51e3fe96820_13"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter Product and Pipeline Update</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided the following updates on selected product and pipeline programs&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Oncology</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tarlatamab (AMG 757)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, data were presented from the global Phase 2 DeLLphi-301 study and simultaneously published in the </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, evaluating tarlatamab, a first-in-class investigational delta-like ligand 3 (DLL3) targeting BiTE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (bispecific T-cell engager) molecule, in patients with advanced-stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment. With a median follow-up of 10.6 months, an intention-to-treat analysis that included 100 patients at the selected 10 mg dose for tarlatamab demonstrated an objective response rate (ORR&#59; primary endpoint) of 40% (97.5% confidence interval&#58; 29-52). There were no new safety signals observed compared to the Phase 1 study.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Data from the DeLLphi-301 study are being submitted to the U.S. Food and Drug Administration (FDA) which recently granted Breakthrough Therapy Designation to tarlatamab for the treatment of adult patients with extensive-stage SCLC with disease progression on or after platinum-based chemotherapy.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLphi-304, a Phase 3 study comparing tarlatamab with standard of care chemotherapy in second-line SCLC, is enrolling patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Two additional Phase 3 studies of tarlatamab in earlier lines of SCLC are planned.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLphi-300, a Phase 1 study of tarlatamab in relapsed&#47;refractory SCLC, continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLphi-302, a Phase 1b study of tarlatamab in combination with AMG 404, an anti-programmed cell death protein 1 (PD1) monoclonal antibody, in second-line or later SCLC, is ongoing.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLphi-303, a Phase 1b study of tarlatamab in combination with standard of care in first-line SCLC, continues to enroll patients.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLpro-300, a Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer, has completed enrollment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BLINCYTO</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In September, based upon the E1910 study, the FDA granted Breakthrough Therapy Designation to BLINCYTO for the treatment of adult and pediatric patients with CD19-positive, Philadelphia chromosome-negative (Ph-), B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of multiphase therapy. Global regulatory </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 8</font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authority submissions are planned in late 2023 to early 2024 for the Phase 3 E1910 study conducted by the National Cancer Institute, the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG ACRIN) Cancer Research Group.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, National Comprehensive Cancer Network</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical Practice Guidelines in Oncology</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (NCCN Guidelines</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) for Pediatric Acute Lymphoblastic Leukemia were updated to broaden the recommendation for BLINCYTO as consolidation to include both early and late first relapse patients with bone marrow relapse with or without extramedullary involvement and adding the COG1331 regimen to the list of recommended treatment regimens.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy in older adults with newly diagnosed Ph- B-ALL, continues to enroll patients.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1&#47;2 study of subcutaneous BLINCYTO in adults with relapsed or refractory Ph- B-ALL continues to enroll patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Xaluritamig (AMG 509)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, initial data from a Phase 1b study were presented and simultaneously published in </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cancer Discovery</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on xaluritamig, a first-in-class bispecific molecule targeting six-transmembrane epithelial antigen of prostate 1 (STEAP1) demonstrating encouraging anti-tumor activity in heavily pretreated patients with metastatic castrate-resistant prostate cancer (mCRPC).  Efficacy was greater at higher doses (doses &#8805;0.75 mg target dose) where PSA50 was 59% (n&#61;44) and RECIST objective response rate was 41% (n&#61;37). The safety profile was clinically manageable, with CRS that was generally low grade and primarily in cycle 1.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1b monotherapy and combination dose-escalation and expansion study of xaluritamig in mCRPC continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Two additional Phase 1 studies of xaluritamig to evaluate preliminary efficacy and safety in patients with early prostate cancer are planned.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 193</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Initial results from a Phase 1&#47;1b study of AMG 193, a first-in-class small molecule methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, demonstrate promising monotherapy activity across six methylthioadenosine phosphorylase (MTAP)-null tumor types. Dose-limiting adverse events and treatment discontinuations were typically due to gastrointestinal events and were manageable and reversible.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">This Phase 1&#47;1b&#47;2 study of AMG 193 continues to enroll patients with advanced MTAP-null solid tumors. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1&#47;2 study of AMG 193 in combination with IDE397, an investigational methionine adenosyltransferase 2A (MAT2A) inhibitor, is enrolling patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 9</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LUMAKRAS&#47;LUMYKRAS </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, data were presented and simultaneously published in the </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS (960 mg or 240 mg) in combination with Vectibix. Both doses demonstrated a statistically significant superiority in PFS over the investigator's choice of standard therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (CRC). No new safety signals were observed. Discussions continue with regulatory agencies on a potential approval pathway for this indication.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In September, LUMAKRAS was included in the colon cancer and the rectal cancer NCCN Guidelines</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (category 2A) and is recommended for treatment of previously treated metastatic colorectal or rectal cancer with KRAS G12C-mutated tumors in combination with cetuximab or panitumumab.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company is planning to initiate a Phase 3 study of LUMAKRAS in combination with Vectibix and FOLFIRI in first-line KRAS G12C-mutated CRC.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In September, data were presented from an arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced NSCLC. LUMAKRAS treatment resulted in encouraging objective response rates and disease control rates in first-line and second-line patients.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A global, randomized Phase 3 study of LUMAKRAS plus chemotherapy vs. pembrolizumab plus chemotherapy in first-line KRAS G12C-mutated and programmed cell death protein ligand-1 (PD-L1) negative advanced NSCLC was initiated.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Regulatory review by the FDA and the European Medicines Agency (EMA) of the CodeBreaK 200 Phase 3 trial of previously treated patients with KRAS G12C-mutated advanced NSCLC along with data from the Phase 2 dose comparison substudy is ongoing. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In November, data</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> comparing sotorasib 960 mg versus 240 mg in adults with pretreated KRAS G12C-mutated advanced NSCLC will be presented at a European Society for Medical Oncology (ESMO) Virtual Plenary session.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bemarituzumab</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-101, a Phase 3 study of bemarituzumab, a first-in-class fibroblast growth factor receptor 2b (FGFR2b) targeting monoclonal antibody, plus chemotherapy in first-line gastric cancer, continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-102, a Phase 1b&#47;3 study of bemarituzumab plus chemotherapy and nivolumab in first-line gastric cancer, continues to enroll patients in the Phase 3 portion of the study.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-103, a Phase 1b study of bemarituzumab plus oral chemotherapy regimens with or without nivolumab in first-line gastric cancer, continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-301, a Phase 1b&#47;2 basket study of bemarituzumab monotherapy in solid tumors with FGFR2b overexpression, is ongoing.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-201, a Phase 1b study of bemarituzumab monotherapy and in combination with standard of care therapy, in squamous NSCLC with FGFR2b overexpression, will be discontinued.</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 10</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 340 </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 dose-escalation study of AMG 340, a lower T-cell affinity BiTE molecule targeting prostate-specific membrane antigen (PSMA), in mCRPC will be discontinued.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Medicine</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Maridebart cafraglutide (AMG 133)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of maridebart cafraglutide, a multispecific molecule that inhibits the gastric inhibitory polypeptide receptor (GIPR) and activates the glucagon like peptide 1 (GLP-1) receptor, in overweight or obese adults with or without type 2 diabetes mellitus has completed enrollment with topline data anticipated in late 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 786</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 study of AMG 786, a small molecule obesity program, is ongoing with initial data readout anticipated in H1 2024. This molecule has a different target than AMG 133 and is not an incretin-based therapy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Olpasiran (AMG 890)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 cardiovascular outcomes study of olpasiran, a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver, in participants with atherosclerotic cardiovascular disease and elevated Lp(a) continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In August, data were presented from the final analysis of the Phase 2 OCEAN(a)-DOSE study. The results from the off-treatment extension period (at least 24 weeks since the last dose) show that patients previously dosed every 12 weeks for up to 36 weeks with &#8805; 75 mg of olpasiran sustained a &#126; 40-50% placebo-adjusted percent reduction in Lp(a) nearly a year after the last dose. No new safety concerns were identified during the off-treatment extension period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Repatha</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">New data from the FOURIER Open Label Extension (OLE) study reinforcing the safety and efficacy of Repatha, including results from the evaluation of long-term neurocognitive safety in atherosclerotic cardiovascular disease patients treated with Repatha, will be presented at the American Heart Association Scientific Sessions in November.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">EVOLVE-MI, a Phase 4 study of Repatha administered shortly after an acute myocardial infarction and designed to reduce the risk of cardiovascular events in hospitalized acute coronary syndrome patients, continues to enroll patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 cardiovascular outcomes study (VESALIUS-CV) in patients at high cardiovascular risk without prior myocardial infarction or stroke is ongoing.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inflammation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TEZSPIRE</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In severe asthma, the WAYFINDER Phase 3b study is fully enrolled.  The PASSAGE Phase 4 real-world effectiveness study and the SUNRISE Phase 3 study continue to enroll patients.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of TEZSPIRE in chronic rhinosinusitis with nasal polyps is fully enrolled. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of TEZSPIRE in eosinophilic esophagitis continues to enroll patients.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 11</font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of TEZSPIRE in chronic obstructive pulmonary disease is fully enrolled. Data readout is anticipated in H1 2024. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2b study of TEZSPIRE in chronic spontaneous urticaria did not meet the primary endpoint comparing tezepelumab with placebo in the overall and anti-IgE-na&#239;ve populations at week 16. By the end of the study at week 32 (18 weeks after last dose), a sustained treatment effect was observed in both tezepelumab dose groups in anti-IgE na&#239;ve patients. The Company and its partner AstraZeneca are determining next steps for this indication and plan to publish full results in the future.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rocatinlimab (AMG 451&#47;KHK4083) </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, three posters of post-hoc analysis data from the Phase 2b study of rocatinlimab, a first-in-class anti-OX40 monoclonal antibody, in patients with moderate to severe atopic dermatitis were presented. These included patient reported outcomes data demonstrating the benefit of rocatinlimab.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The ROCKET Phase 3 program, composed of seven studies evaluating rocatinlimab in moderate to severe atopic dermatitis, continues to enroll adult and adolescent patients.  To date, over 1,500 patients have  been randomized into the ROCKET program.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of rocatinlimab in moderate to severe uncontrolled asthma is planned.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Otezla</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In October, results were presented from the DISCREET Phase 3 study which demonstrated that Otezla treated patients across subgroups experienced greater improvement in genital psoriasis and genital itch at week 16 compared to placebo, with women achieving numerically greater responses.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study evaluating the efficacy and safety of Otezla in Japanese patients with palmoplantar pustulosis successfully met the primary and secondary endpoints.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TAVNEOS</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Data will be presented from the ADVOCATE study at the American College of Rheumatology and American Society of Nephrology Scientific sessions in November on the efficacy and safety of TAVNEOS in key sub-groups including patients 65 years old and older and patients with renal involvement.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Efavaleukin alfa (AMG 592)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2b study of efavaleukin alfa, an interleukin 2 (IL 2) mutein Fc fusion protein, in ulcerative colitis continues to enroll patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ordesekimab (AMG 714&#47;PRV-015)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2b study of AMG 714, a monoclonal antibody that binds interleukin-15, in nonresponsive celiac disease continues to enroll patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biosimilars</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The clinical comparative study portion of a randomized, double-blind pivotal study evaluating pharmacokinetic (PK) similarity of ABP 206 compared with OPDIVO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (nivolumab) in resected stage III or stage IV melanoma patients in the adjuvant setting was initiated.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 12</font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The FDA accepted the Biologics License Application for ABP 938, an investigational biosimilar to EYLEA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (aflibercept).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Comprehensive Cancer Network</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> (NCCN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Previously provided in the publicly available ODAC briefing book.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE is being developed in collaboration with AstraZeneca.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rocatinlimab, formerly AMG 451&#47;KHK4083, is being developed in collaboration with Kyowa Kirin.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company.  For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IDE397 is an investigational MAT2A inhibitor from IDEAYA Biosciences.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">OPDIVO is a registered trademark of Bristol-Myers Squibb Company.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.</font></div><div id="if4b5ec9552554732b4cde51e3fe96820_16"></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 13</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this news release, management has presented its operating results for the third quarters of 2023 and 2022, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2023 EPS and tax guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, divestitures, restructuring and certain other items from the related GAAP financial measures. Beginning January 1, 2022, following industry guidance from the U.S. Securities and Exchange Commission, the Company no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&#38;D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transactions from its non-GAAP financial measures. Management has presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the third quarters of 2023 and 2022. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s normal and recurring business activities by facilitating comparisons of results of normal and recurring business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Amgen</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of &#8220;America&#8217;s Greatest Workplaces&#8221; by Newsweek, one of &#8220;America&#8217;s Climate Leaders&#8221; by USA Today and one of the &#8220;World&#8217;s Best Companies&#8221; by TIME.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, TikTok, YouTube and Threads.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 14</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 15</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain&#59; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such acquisition or integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACT&#58; Amgen, Thousand Oaks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jessica Akopyan, 805-440-5721 (media)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Justin Claeys, 805-313-9775 (investors)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_19"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 16</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Income - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,077&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,249&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,652&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,994&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,484&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,368&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,626&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,054)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in calculation of earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_22"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 17</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Balance Sheets - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,305&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,026&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,477&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,186&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,509&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,529&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,534&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,121&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,526&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,954&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,687&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,040&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,354&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,656&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,534&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,121&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_25"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 18</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,588&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,339&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,659&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to cost of sales&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(668)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(585)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,008)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,779)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(585)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,779)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,137&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,003&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,880&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to research and development expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to research and development expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,206&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,050&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,842&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to selling, general and administrative expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(151)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,293&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,276&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,754&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,802&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,882&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,992&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,368&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,148&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(585)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,779)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(151)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(183)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(628)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(691)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(544)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,382)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(617)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,113)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,416)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,500&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,375&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,255&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,732&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 19</font></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,021&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,660&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,626&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,336&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,382&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,416&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,403&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,277&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,739&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,752&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP interest expense, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(759)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(368)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,054)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(991)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to interest expense, net&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense on acquisition-related debt (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP interest expense, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(427)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(368)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,266)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(991)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP other income (expense), net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(747)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to other income (expense), net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income and other expenses on acquisition-related debt (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(607)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity method investment basis difference amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (gains)&#47;losses from equity investments (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(170)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,305)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">401&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to other income (expense), net</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(103)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,912)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP other income (expense), net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(203)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP income before income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,947&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,598&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to income before income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,382&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,416&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(103)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,912)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to income before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,231&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">514&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,960&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP income before income taxes</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,178&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,906&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,992&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,558&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP provision for income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,053&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">662&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (f) </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">527&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP provision for income taxes</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">511&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">376&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,501&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,190&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (f) </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,936&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to net income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to income before income taxes, net of the income tax effect</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,433&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to net income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,541&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,432&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,530&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,491&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,368&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_28"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 20</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the computations for GAAP and non-GAAP diluted earnings per share&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>September 30, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,143&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.22&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine months ended<br>September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine months ended<br>September 30, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,491&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,936&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,368&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.06&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.92&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.11&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.59&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:3.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related primarily to noncash amortization of intangible assets from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2023, the adjustments related primarily to separation costs associated with our restructuring plan initiated in early 2023.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2023, the adjustments related primarily to a net impairment charge for AMG 340. For the three months ended September 30, 2022, the adjustments related primarily to an impairment charge associated with an in-process research and development asset. For the nine months ended September 30, 2022, the adjustments related primarily to cumulative foreign currency translation adjustments from the divestiture of Gensenta.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2023, the adjustments included (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit and term loan credit agreements, incurred prior to the closing of our acquisition of Horizon Therapeutics plc.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the nine months ended September 30, 2023, the adjustments related primarily to our BeiGene, Ltd. equity fair value adjustment.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets and certain gains and losses on our investments in equity securities, whereas the tax impact of other adjustments, including expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rate for the adjustments to our GAAP income before income taxes for the three and nine months ended September 30, 2023, were 22.0% and 22.2%, respectively, compared to 23.7% and 17.8% for the corresponding periods of the prior year.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(g)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related to certain acquisition items, prior period and other items excluded from GAAP earnings.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_31"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 21</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliations of Cash Flows </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:52.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,072&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,571)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,294&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash and cash equivalents</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,248&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,203&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,072&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(863)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,070&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if4b5ec9552554732b4cde51e3fe96820_37"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 22</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP EPS Guidance to Non-GAAP </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EPS Guidance for the Year Ending December 31, 2023</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Known adjustments to arrive at non-GAAP*&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net charges related to restructuring and cost savings initiatives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)&#47;losses from equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.90)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.80&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* The known adjustments are presented net of their related tax impact, which amount to approximately $1.50 - $1.69 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) The adjustments include noncash amortization of intangible assets and fair value step-up of inventory acquired in business combinations and the net impairment charge for AMG 340, as well as transaction, integration and employee-related costs. Adjustments above include a preliminary range for the projected impact from the October 6, 2023 Horizon Therapeutics plc (Horizon) acquisition to be recognized in the fourth quarter of 2023. The initial accounting for the Horizon acquisition is incomplete, pending identification and measurement of assets acquired and liabilities assumed, and as a result this preliminary projected range of adjustments related to this acquisition is subject to change.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP Tax Rate Guidance to Non-GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate Guidance for the Year Ending December 31, 2023</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:74.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate of known adjustments discussed above</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20231031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:adc26e5c-240e-4a1e-ac94-a7cdfbd97ce7,g:9497942b-b8bf-4481-98ae-facda9fa8df2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20231031" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20231031">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20231031_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.amgen.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_CoverPageAbstract" abstract="true" name="CoverPageAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20231031_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:adc26e5c-240e-4a1e-ac94-a7cdfbd97ce7,g:9497942b-b8bf-4481-98ae-facda9fa8df2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20231031.xsd#CoverPageDocument"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8fb8402b-3454-457f-933e-821968144d08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityCentralIndexKey_8fb8402b-3454-457f-933e-821968144d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f5df87a7-2fd9-4be5-a201-4ea43c737939" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_AmendmentFlag_f5df87a7-2fd9-4be5-a201-4ea43c737939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e10d97ff-9e86-4bfd-9844-82cdfa2a50cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_SecurityExchangeName_e10d97ff-9e86-4bfd-9844-82cdfa2a50cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3e6323eb-9709-4244-a17d-88e6dc84e580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3e6323eb-9709-4244-a17d-88e6dc84e580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_173a6b6a-6c53-48c1-9194-2101db6f5efe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_PreCommencementTenderOffer_173a6b6a-6c53-48c1-9194-2101db6f5efe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cae1c48f-896a-42e0-a2a0-eb4d60fe3653" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_SolicitingMaterial_cae1c48f-896a-42e0-a2a0-eb4d60fe3653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3d5f20c4-7d67-4ba1-9796-4a66ee9555b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_WrittenCommunications_3d5f20c4-7d67-4ba1-9796-4a66ee9555b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bce0ac2e-93ca-41b9-9977-8da8f4f44289" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bce0ac2e-93ca-41b9-9977-8da8f4f44289" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09887839-5431-45c1-89cf-58fd483520b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_DocumentType_09887839-5431-45c1-89cf-58fd483520b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5ebe194b-77b3-47dc-a634-3d5799ee135d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_DocumentPeriodEndDate_5ebe194b-77b3-47dc-a634-3d5799ee135d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f4fe640-602f-40c1-9b30-a11bc9d66977" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityRegistrantName_9f4fe640-602f-40c1-9b30-a11bc9d66977" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fe25ab73-4385-4674-b6dd-a37cbd2cffaa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityFileNumber_fe25ab73-4385-4674-b6dd-a37cbd2cffaa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_31f7b9e8-ca1a-49ae-b25c-4a4ff763f0a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityTaxIdentificationNumber_31f7b9e8-ca1a-49ae-b25c-4a4ff763f0a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b80014ed-0665-4c66-a7b7-4a9cf7ccb422" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressAddressLine1_b80014ed-0665-4c66-a7b7-4a9cf7ccb422" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cf471e5d-4785-4d09-91cc-b34183997635" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressCityOrTown_cf471e5d-4785-4d09-91cc-b34183997635" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f72462e0-0f1a-42b2-bc8d-36dd2b61b385" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressStateOrProvince_f72462e0-0f1a-42b2-bc8d-36dd2b61b385" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f37e43b8-953d-4f5f-b79f-a0a82ed0f346" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressPostalZipCode_f37e43b8-953d-4f5f-b79f-a0a82ed0f346" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e7a0df48-03ec-43cf-b2d8-2c5500287fdd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_CityAreaCode_e7a0df48-03ec-43cf-b2d8-2c5500287fdd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b77ab9d8-6ba3-40e6-9799-3a79b5b01356" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_LocalPhoneNumber_b77ab9d8-6ba3-40e6-9799-3a79b5b01356" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3105deaf-f877-41fd-8767-b01f3254a7c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityEmergingGrowthCompany_3105deaf-f877-41fd-8767-b01f3254a7c8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1a36be1f-584b-40b7-bc52-c7a646f53260" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_TradingSymbol_1a36be1f-584b-40b7-bc52-c7a646f53260" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_28d8f9b3-2875-4b20-8e2d-9d2fc156b103" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_Security12bTitle_28d8f9b3-2875-4b20-8e2d-9d2fc156b103" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:to="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:to="loc_dei_ExchangeDomain_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:to="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_b71039ff-3e58-4d70-9870-4a9aa7bc4538" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:to="loc_exch_XNGS_b71039ff-3e58-4d70-9870-4a9aa7bc4538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_477b0e15-a44b-4aa6-abc1-23531a44d580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:to="loc_us-gaap_ClassOfStockDomain_477b0e15-a44b-4aa6-abc1-23531a44d580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:to="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2682f1e0-9ef2-4463-8197-5b5db83f4da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:to="loc_us-gaap_CommonStockMember_2682f1e0-9ef2-4463-8197-5b5db83f4da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_151f58bc-813c-47c2-9efb-a3c04264a576" xlink:href="amgn-20231031.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_151f58bc-813c-47c2-9efb-a3c04264a576" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20231031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:adc26e5c-240e-4a1e-ac94-a7cdfbd97ce7,g:9497942b-b8bf-4481-98ae-facda9fa8df2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_ExchangeDomain_c02366a8-20c4-4feb-a4b7-3bc87ef7ca9d_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_386f79ac-3f58-4e8c-af58-096583361d93_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f0d5f916-0161-4e82-b9a6-062ad09a6052_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_fb4a63d3-f1f5-444e-a643-7f16f42a769e_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d28c365f-f528-4376-a9ad-7b504d1b6db4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_601d8af2-ebd4-4b83-ba23-2088e6f11420_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d0b3f457-c533-4932-8fd5-7f65184fd852_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_75743415-63c5-401b-b03b-e36248a6a705_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_42219275-04c2-4a05-bd99-621444721d21_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a87e653b-42cb-4f58-bccf-93114dcd7b43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9de113ee-0ba9-4c5a-8a8e-06322d5655c9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9800037d-12f3-4c46-9273-e95107aaa254_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_165119bc-08d9-4d7d-9bdd-bfa9f4d3fe28_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20231031.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CoverPageAbstract_2f94fd52-fe77-4f0d-964c-ce2de255b617_terseLabel_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_label_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_documentation_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract" xlink:href="amgn-20231031.xsd#amgn_CoverPageAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CoverPageAbstract" xlink:to="lab_amgn_CoverPageAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_503a6b3b-fe03-400a-8025-eb3855bd7cdf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_fca98536-f86f-4a40-89d3-716f69fb1193_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6df26ac4-1483-4f2e-9183-4a331be3dc7b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e4f22db5-b204-442b-9943-ff0438064f6c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1683af42-65fb-4480-8a46-68c4c9a19038_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_477bc771-954d-4617-865e-0d60eeef1293_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2660855c-7ab7-49d9-a554-f50c2d48055b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f359307d-9a76-4cd2-a6ba-f0e019e44d38_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_317cd5d4-a1bf-456b-9a00-6b5b61537420_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_4a22e0a8-debb-4f11-8d16-197bf6f24a76_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fc7b252f-c298-4a9a-b9b9-11f946713ee9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c449e4d3-baf6-4827-a1cc-bcf14df6450b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d5c9c296-dcde-471c-8d02-4a82330a2d92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d6ce8440-78a4-4211-b8a2-f3425bf432c2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_8aa589d0-ba13-4886-afb8-0dadb01f9ed4_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b79fab76-6636-46d6-83ed-7eb8db167536_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d443db97-8ac7-4c47-8734-c42bcfc009b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_39748d3b-446b-4695-b9a1-2da11794f1ee_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20231031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:adc26e5c-240e-4a1e-ac94-a7cdfbd97ce7,g:9497942b-b8bf-4481-98ae-facda9fa8df2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20231031.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract_253bbaac-00b9-4c8f-9ca6-ab1454fb383d" xlink:href="amgn-20231031.xsd#amgn_CoverPageAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_CoverPageAbstract_253bbaac-00b9-4c8f-9ca6-ab1454fb383d" xlink:to="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:to="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_c50e90b6-3a77-4ff5-bd4e-8567a1a5e175" xlink:to="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_b71039ff-3e58-4d70-9870-4a9aa7bc4538" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_517d710a-8162-4571-baef-b2cab0b60dff" xlink:to="loc_exch_XNGS_b71039ff-3e58-4d70-9870-4a9aa7bc4538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_477b0e15-a44b-4aa6-abc1-23531a44d580" xlink:to="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2682f1e0-9ef2-4463-8197-5b5db83f4da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:to="loc_us-gaap_CommonStockMember_2682f1e0-9ef2-4463-8197-5b5db83f4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_151f58bc-813c-47c2-9efb-a3c04264a576" xlink:href="amgn-20231031.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_40befad2-ecb3-4920-8e9f-77b23e76eac1" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_151f58bc-813c-47c2-9efb-a3c04264a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4f3d6b12-cf18-4a11-9ef2-6b2154e6dc65" xlink:to="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8fb8402b-3454-457f-933e-821968144d08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityCentralIndexKey_8fb8402b-3454-457f-933e-821968144d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f5df87a7-2fd9-4be5-a201-4ea43c737939" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_AmendmentFlag_f5df87a7-2fd9-4be5-a201-4ea43c737939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e10d97ff-9e86-4bfd-9844-82cdfa2a50cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_SecurityExchangeName_e10d97ff-9e86-4bfd-9844-82cdfa2a50cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3e6323eb-9709-4244-a17d-88e6dc84e580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3e6323eb-9709-4244-a17d-88e6dc84e580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_173a6b6a-6c53-48c1-9194-2101db6f5efe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_PreCommencementTenderOffer_173a6b6a-6c53-48c1-9194-2101db6f5efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cae1c48f-896a-42e0-a2a0-eb4d60fe3653" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_SolicitingMaterial_cae1c48f-896a-42e0-a2a0-eb4d60fe3653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3d5f20c4-7d67-4ba1-9796-4a66ee9555b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_WrittenCommunications_3d5f20c4-7d67-4ba1-9796-4a66ee9555b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bce0ac2e-93ca-41b9-9977-8da8f4f44289" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bce0ac2e-93ca-41b9-9977-8da8f4f44289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09887839-5431-45c1-89cf-58fd483520b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_DocumentType_09887839-5431-45c1-89cf-58fd483520b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5ebe194b-77b3-47dc-a634-3d5799ee135d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_DocumentPeriodEndDate_5ebe194b-77b3-47dc-a634-3d5799ee135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f4fe640-602f-40c1-9b30-a11bc9d66977" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityRegistrantName_9f4fe640-602f-40c1-9b30-a11bc9d66977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fe25ab73-4385-4674-b6dd-a37cbd2cffaa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityFileNumber_fe25ab73-4385-4674-b6dd-a37cbd2cffaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_31f7b9e8-ca1a-49ae-b25c-4a4ff763f0a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityTaxIdentificationNumber_31f7b9e8-ca1a-49ae-b25c-4a4ff763f0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b80014ed-0665-4c66-a7b7-4a9cf7ccb422" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressAddressLine1_b80014ed-0665-4c66-a7b7-4a9cf7ccb422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cf471e5d-4785-4d09-91cc-b34183997635" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressCityOrTown_cf471e5d-4785-4d09-91cc-b34183997635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f72462e0-0f1a-42b2-bc8d-36dd2b61b385" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressStateOrProvince_f72462e0-0f1a-42b2-bc8d-36dd2b61b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f37e43b8-953d-4f5f-b79f-a0a82ed0f346" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityAddressPostalZipCode_f37e43b8-953d-4f5f-b79f-a0a82ed0f346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e7a0df48-03ec-43cf-b2d8-2c5500287fdd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_CityAreaCode_e7a0df48-03ec-43cf-b2d8-2c5500287fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b77ab9d8-6ba3-40e6-9799-3a79b5b01356" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_LocalPhoneNumber_b77ab9d8-6ba3-40e6-9799-3a79b5b01356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3105deaf-f877-41fd-8767-b01f3254a7c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_EntityEmergingGrowthCompany_3105deaf-f877-41fd-8767-b01f3254a7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1a36be1f-584b-40b7-bc52-c7a646f53260" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_TradingSymbol_1a36be1f-584b-40b7-bc52-c7a646f53260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_28d8f9b3-2875-4b20-8e2d-9d2fc156b103" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_c37d5472-d1e3-4258-9b34-aef2167a8589" xlink:to="loc_dei_Security12bTitle_28d8f9b3-2875-4b20-8e2d-9d2fc156b103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>amgenlogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgenlogoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ") ;H# 2(  A$! Q$!_\0
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M-<?\)!"V[_EDUE"4'T&VOG^BOJ(Y+EL598>'_@*/G)9MF$G=UY?>SZC\-_\
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M]P**** "BBB@ K!\=>--,^'OA+4_$.KSI;V-C"TKLQQN/\*C@\L< <=ZWJ^
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M3VK#J5*,FXIZK<IQDDI-:,[/X/\ Q(OOA/\ $/1_$MB[!K28>;&"0)8CPZ$
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ME\9_^AVF_P# &U_^-5]5]3XG_P"@J'W+_P"0/F_K7#O_ $#3^_\ ^W/>(_\
M@F3=1NKK\1(@RG((TANO_?\ IG_!1:SNM.\*_#&TOIXKJ\@CNHI9H8S&CL%@
M!8*68@''0D_6O"O^&TOC/_T.TW_@#:__ !JN+^)'QM\:_%Z.P3Q=KDFL+8ES
M;AX(H_++[=WW$7.=J]?2M<+EF<2QM'$8^M&<:=]E9ZJW\J\C+$YAE4<'5H8&
ME*,IVWU6C3_F9PU%%%?<'QQ^O?[*?_)O'@;_ *\/_9VKUBOR%\+_ +5?Q4\%
M^'[+1-&\62V6EV4?E6]NMI;N$7).,M&2>2>IK4_X;2^,_P#T.TW_ ( VO_QJ
MOR#%\'8[$8BI6C4A:4F]WU=_Y3]4PO%>#H8>G2E"5XI+9=%;N?K-65XJ_P"1
M7UC_ *\YO_0#7Y7?\-I?&?\ Z':;_P  ;7_XU7Z!? _Q=J_CS]F73=>UZ\.H
M:M>:=>-/<LBH7*R2J.%  X4#@=J^>S'AW%91"%>O*+3DEI?S?5+L>[@,^P^:
M3G1HQDFDWK;TZ-]S\DI/]8WU--ITG^L;ZFFU_0+W/PU;!1112&?8_P"Q#^U)
M<>&]6L_A_P"*;Z/^P+@E-.O+I\&TE/2/=TV,?7H3[TG_  4L_P"2B>$_^P4W
M_HYZ^.@2I!'!KT#XI?&+4OBQI?A2+5XPU_H=A_9YNEX\] Y*$CL0#@GOBOEG
MDL*6;0S&@K)W4EYM/7Y]?O[GTBS:53+)X"L[M6Y7Y)K3Y=/N['GU%%%?4GS9
M^E?_  3I_P"2(ZA_V%I/_1<=?5%?*_\ P3I_Y(CJ'_86D_\ 1<=?5%?SEQ!_
MR-,1_B9^^9'_ ,BVA_A04445\^>X%%%% !1110!R?Q5^(%E\+?A[KGBB_(,.
MGV[2*F<>9(?EC0''5G*K^-?C3XC\07OBK7M0UC4IC<7]].]Q-(W=F))_#FOL
MW_@I#\4A<:AH/@*RN04MU_M+4$3:?G;*PH2#D$+O8J?[R'TKXAK]PX/RY87!
M?69KWJG_ *2MOOW^X_'.*L>\3B_J\7[M/\WO]VWWA6KX5TFVU[Q%I]A>ZC#I
M%G/,J37UQDI G\3$ 9.!G@=3@5E45]Y)-II.Q\7%I--JY^IW@#]H3X$?#/PC
MI_AS0?%5I:Z;9)M1?*F+,Q.6=CLY9B22?4UT/_#8'PA_Z'.U_P"_,O\ \17Y
M(45\!/@O!5).<ZLVWJW=?Y'V\.+<73BH0IP26VC_ ,SVG]KSQMHGQ!^-VJ:S
MX?OTU+3)8852XC5@"0@!X(!ZUXM117V^%P\<+0A0@[J*2^X^/Q%:6)K3K2WD
MV_O%7[P^M?IG\8/^3#;+_L7-,_\ 1<-?F8OWA]:_3/XP?\F&V7_8N:9_Z+AK
MY#B3^/@?^OB_0^IX?_@XS_KV_P!3\RZ***^X/CCZH_X)S1K-\<-51U#HV@7"
MLK#((,T'!KSK]J_X/CX-?&#4].M(?+T2^_T_3MH^587)S&/]Q@R@9SM"D]:]
M'_X)Q?\ )=-3_P"P#<?^CH*]U_X*+_#]->^%>F^*(D3[5H-X$DD>0@^1,0C*
MJ]&/F"(\] #7Y[6Q[P?$JI-^[4C&+]>GXZ?,^ZIX)8KA]U$O>IR;7II?\-?D
M?G!70^%_&^H^$]/UZRM&!MM:LOL5U&^=I7>KAL>H*#!]S7/45^@2C&:Y9*Z/
MAXRE!WB[,*?#$T\J1H-SN0H'N:97L'[)OP\7XD_';PUI\\!GT^VF^W78,)DC
M\N(;]K]@K,%3)[N*QQ->.%HSKSVBF_N-L/1EB*T*,-Y-+[S[(@^#\?P:_8E\
M4Z;- (]9O=(DO=18C#"5E&(S_N+A<=,[B.M?FO7["_M.?\F_^//^P5+_ "K\
M>J^)X0Q%3%4<17JN\I3N_N1]?Q30AAJM"C35HQA9?>PHHHK[X^("G1?ZQ/J*
M;2JVU@1V.::W _;OP?\ \BEHG_7C!_Z+6M>O./V=_'D?Q&^#?A?6DDC>9K18
M+@1*RJDL8V,N#Z$?2O1Z_EK$TY4:\Z<U9IM/[S^D,/4C5HPJ0=TTG^!1US_D
M":A_U[R?^@FOP^N/]?)_O&OW!US_ ) FH?\ 7O)_Z":_#^X4^=)Q_$:_4.!?
MAQ'_ &[_ .W'YSQGO0_[>_\ ;2*BEVGTHVGTK]4/S42BE*D=124 %%%% !11
M10 44NT^E&T^E "5^J_[,/\ R:#H/_8-OO\ T=/7Y4[3Z5^JW[,/_)H6@_\
M8-OO_1T]? <9_P"Y4O\ KXORD?;\)_[W5_P/\T?E5)_K&^IIM.D_UC?4TVOT
M![GPZV% +$ #)/:@@J2",$5<T7_D,6/_ %W3_P!"%?7_ .W=^S7#X7N/^%B>
M&;&*VTFY<#5[>)@JQ3NP"RJGHY."!T;!QR<>7B,PI87%4<-4T=2]GYJVGSOI
M]QZ5# U<1AZN(IZJG:Z\G?7Y6U/C.BBBO3/."BBB@#]*_P#@G3_R1'4/^PM)
M_P"BXZ^J*^5_^"=/_)$=0_["TG_HN.OJBOYRX@_Y&F(_Q,_?,C_Y%M#_  H*
M***^?/<"BBB@ JOJ&H6VDV%S?7D\=K9VT3333RL%2-%!+,Q/0  DGVJQ7@7[
M;OQ$?P#\!M5AMI6BOM;D73(BCJ&5'!:4X/52BLAQT\P5VX+#2QF)IX>.\FD<
MF+Q$<)AYUY;139^:_P 6_'MS\3OB1XA\3W6X-J-V\D:,P8QQ#Y8TR ,[4"KG
MVKD:**_IRG3C1A&G!625EZ(_G:I4E5FZDW=MW?S"BOH7]E3]EN+]H1==NM1U
M.YTC3M/V1I/;(CEY6R=I#>PSFOH'_AV?X:_Z'35?_ 6*OG\9Q%EV!K2P]>=I
M+?1OSZ'N87(L?C**KT87B]M4C\^:*_0;_AV?X:_Z'35?_ 6*C_AV?X:_Z'35
M?_ 6*N/_ %MRG_GX_P#P%_Y'7_JQFG_/M?\ @2_S/SYHKTG]H3X5VGP9^)VH
M>%[*_FU*WMHXW%Q<($8[E!(P..]>;5]50K0Q%*-:F[QDKKT9\U6I3H5)4JBU
MB[/Y"K]X?6OTS^,'_)AME_V+FF?^BX:_,Q?O#ZU^F?Q@_P"3#;+_ +%S3/\
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MN*JU*=/1R;7O+9OU/V3!Y]E=+#4J<ZFJBD]'NEZ'VI_PCND_] NS_P# =/\
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M ,M@HHHKZ \,_2O_ ()T_P#)$=0_["TG_HN.OJBOE?\ X)T_\D1U#_L+2?\
MHN.OJBOYRX@_Y&F(_P 3/WS(_P#D6T/\*"BBBOGSW HHHH *_.?_ (*.>/CK
M7Q*TCPM$Y,&B6GF2*T8!$TV&.&[C8(OH<U^BEQ<16=O+//(L,$2EY))" JJ!
MDDD] !7XP?&#QDWQ!^)WB7Q"P*+?WTLR(9?,"(6.U0W< 8 ^E?H7!>$]MC98
MAK2"_%Z?E<^%XNQ7LL'&@MYO\%K^=CCZ**OZ!I<FN:Y8:?%D274Z0J0I;EF
MZ=^M?M3:BKL_(DFW9'Z>_L*>"!X2^ NG7CPP)=:S-)>O)$22Z9VH&]P%/'O7
MT/67X7T./PSX;TK2(BK1V-K%;!E3:&V*%SCMG&?QK4K^8L?B7C,54Q#^TV_\
MOP/Z*P6'6$PU.@OLI+_,****X#M/RM_;J_Y.+US_ *XP?^BQ7S]7T#^W5_R<
M7KG_ %Q@_P#18KY^K^ELG_Y%V'_P1_)'\^9K_O\ 7_Q2_,5?O#ZU^F?Q@_Y,
M-LO^Q<TS_P!%PU^9B_>'UK],_C!_R8;9?]BYIG_HN&OGN)/X^!_Z^+]#W.'_
M .#C/^O;_4_,NBBBON#XX^JO^"<7_)=-3_[ -Q_Z.@K]*:_-;_@G%_R734_^
MP#<?^CH*_2FOPGC'_D:/_#$_9^%/^1:O\3/R&_:PTFTT/]H;QO:V4*P6_P!M
M\T1KTW.BNQ_%F)_&O):]F_;%_P"3D_&__7S'_P"B8Z\9K]ERUN6!H-_R1_\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139730509840304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | 2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>amgn-20231031_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20231031"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:exch="http://xbrl.sec.gov/exch/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20231031.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-26">2023-10-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-27">2023-10-31</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #H.5]7EXJ[',
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " #H.5]7!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .@Y7U>@&+IL[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .@Y7U>97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Z#E?5XYY7W7Z!   >Q4  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( .@Y7U>?H!OPL0(  .(,   -              "  3P-  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ Z#E?5Y>*NQS     $P(   L
M     ( !&!   %]R96QS+RYR96QS4$L! A0#%     @ Z#E?5]M?!^TY 0
M, (   \              ( ! 1$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( .@Y7U<D'INBK0   /@!   :              "  6<2  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .@Y7U=ED'F2&0$  ,\#
M   3              "  4P3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  )84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="amgn-20231031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="amgn-20231031.htm">amgn-20231031.htm</File>
    <File>amgn-20231031.xsd</File>
    <File>amgn-20231031_def.xml</File>
    <File>amgn-20231031_lab.xml</File>
    <File>amgn-20231031_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "amgn-20231031.htm": {
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20231031",
   "dts": {
    "inline": {
     "local": [
      "amgn-20231031.htm"
     ]
    },
    "schema": {
     "local": [
      "amgn-20231031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20231031_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20231031_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20231031_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 27
   },
   "report": {
    "R1": {
     "role": "http://www.amgen.com/role/CoverPageDocument",
     "longName": "0000001 - Document - Cover Page Document",
     "shortName": "Cover Page Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20231031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20231031.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNGS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNGS",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.amgen.com/20231031",
     "localname": "A2.00SeniorNotesDue2026Member",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "documentation": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "amgn_CoverPageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.amgen.com/20231031",
     "localname": "CoverPageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover Page [Abstract]",
        "label": "Cover Page [Abstract]",
        "documentation": "Cover Page [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000318154-23-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-23-000061-xbrl.zip
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MZ0>"KS\D_'TS.ROIP P^>@^_&#]@YA@_OGRVO-R_]/_+PLMG_P-02P,$%
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M<3 MZ.EU+DR=_<$/B&GA;-E),6UNZ[GJ*+?[,?V4)E]C[<X4$>*&OL]!0%D
M<"0B0'T? ^6[' F=\7V_]6BYKJ.1!I3MZIJM C: .RY".N2W;?SHS]HP@:,#
M8=W7)%6PT7]ATJ'A[[,ZJ<*]RB5*5>U[;YY_MUS>RW1WJ[?R_,ASS?HD&A"
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MZZGF12RZ3P[>>;QCX>>SZ(%%:3.Q#J<@.9;DN"Y2 D$F33,(K<2PC>>!S;7
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M>_+^^J9[<WG=_0C7'SY_?'R8!T"L34R1=',:Y?X;!:'5'[]:"<G-7W0X1.6
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M!;"T,Y-]\Y@3*.(^,'$G!SU'X).3C,5&;8K :Y7Z-($[\Z^:(_)JI;&8QAO
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MA-2$_X6,YY,YB-UHMJ.]#*9E8#D__5!O77QEWU"9'GN,=,C9W>7#[YUS^,:
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M7/.*FJHUW(L>IKJ4[,.=6U>AGKTTE\TLMA908=!.-B;Q\?.G[N_WW;QK#$>
M'$\" ?#]F5/PJ2202;E09GEMKJ&J@+H'9[ARS^PC^IC97.8"*EMG->UD<V[_
M\^'J2QXS1I5W9M+>0<FUO834,\N"\PS6AJ:\,_M0;3N9Q=8"*@PGF_]QXX&0
M9DI=R#&GJ.G*8-M'46]FP^EYAFI=:0M[">AF=SY" ;6%^LFJ"Y^^=!^NE;:0
M8TZAU56^OBHNR0E4=37_=C^#US*KA!506SC=5-'NS;^N;QZ5OI!G7J&LX+U4
MEBBH[D.L*:CN@0%DUKM80%WAK'6Z<]>N[FX_7-TH92''O**A./#I#:;(,V@5
MPIY8X701=89F[61UAJY/'19X2FG(,[?([F3G/(-55TU!]I-MHWPW^P!K0R4P
M'%!E..%)*G?4#VC/>E(Z0X[912.S <P\0S6[9EN>H9K=1/X\0Q7^S2I8BZ@P
M-$Y67[AAD4V#4$UKS3.WZ&0VB)EGJ-845/<RV425_ZK^F+E7&#;T,)A6X-ET
M_,9Q47:M@I&Z,TMW'EX1/ (VWX9#YA//=\W("(-__&.6A9P:+\UP@#?/8%5=
M6?>"K,W,"OY\@S6S/*" ^I1V["*2(^SYT0VI'4M=$E";!=\A>*=!@PZ4%9!9
M2()9@\^/2RAOS2UFFKO42\W.:FFXWBX/PWD4;N4)M[12N[%:)5"XI7!KN[TU
M2XT76OTJW%*XM2UNZ;7\\*T-M?&UEYYM/7UQ9YAX$?+6)@?4UJK[&I#>_% 0
M\#7XGNE&/9NI#^;Q@R\1UEJ+47[Z0MZYQ;&>A)/A'Y=#Z@P8L1S"OADL"(C;
M)WAI%SY^=>N^;UW'P;<&>UL+J[=T)F8RJ^D?_[ATG< *0H[OW2\/MQ_SWC3^
M"% LD?OK[MN;O'>X.0KD+EW?IH[K*]AM#KN;J\]%:)9P%-A=?_KXYX?K2P6Z
MS4'WP$!D>%21[,:PXY/</EDC %X>$XFG!KD= 7R$.B9Y>_7[U:<O"GI;$"X-
MR#.S;?PO#Z.BM>/YENL3#U[IFEP)=".?@#K*@I !L)D_H".7 QX$S</5S6.7
M!%$OL$R+^A8+*@L2R]<S&(7NNT2YSKDU>?.)_/1#4[L@CAN2$:,.K+L?V6O8
MDBN!L[E!I-ZCWK/[]VQG;?\<TI[-8DX!_\RXP^O(/^>9Z[-EAD-)5^FGY-*J
MDT=H#]81A?./"![PZR\]7,44NTK].TS<\QX=L'+/9_1KF?9#YK^A]C,=!].?
M'UE.3//-%F?]:W_UA6OQ%U+\[;]1$%K]\:Z9F?82,]-Y<Y5/P/G)_=7=[?WC
M WG\[?K^'?GC<_?^\>J>O+^^Z=Y<7G<_PO6'SQ\?'Y;L],!+OH,3)(U%9YT^
M0>H/X! E'C7AQ?(O*,Z;TP+F0 ?06KB;6Y#.0 O.@%Q]\T#W9B4R^=,GOF8N
MH!_I-W)/0T:Z#K7'@14L1:T,;GWQ0=["SLB';O>.@"9E!3_]T&A?;+\KR9N$
M=E%;O$_Q)\LQ81=OREJ;,[$C'#IV>].;^]$7UUG!-+ TK5)'2(A<O#F$#,A!
MUKD81RS' %X=@+:JZZ\KAUG)XC.[=(,05>B'=([B$2!"!-Z3%&0J&NKX&"A'
MUNBYEA,&)53^X5;X/C%]D+4.Z8W)$%XDJASZ%BQ\2'W@-_*/8 J COTW17%+
MF#A[TO?=$:'&7Y$EY'"9BV[X* T"%@:<-1D\NB(-#I'(.;*^'?6P[EG J&\,
M05.OM2_(._;$;-<;P1?(V3W_V[OS8Z(UBTG+9/$IUEYS&\YVG^$L KAL(D#]
M>",(:/@)3M.S/&YVDF>XW:-P9M2&/[O]/IQ(ZI"3=^"!^>6 (X<!3Z(=A2<U
M\.E(G"#@R5>&IQJ7OQSU\![ C 7^4R(?F .\R):'V#5!+;."T.>J(SE[^,#_
MWCT_)C$F!SDAQ\;KE;0WD)M"N-/I+<4O*^';[ @Y=$*<"T@POOVHA\7+IHYY
M FXBKY*S,$38"T $_)H2!\@"W7*6SQD L"L?**'O^@2T7U*K5RM*ZSB>UC&K
M[1X3EX"ATK0H!?29*DU(L6M8?FM>ZI+0);5JI?-Z.4IE$V,6 R1S&%,3BJJT
MA8Z)*A-^7UV$"(M% /!*HE=UG=Q%S =4N;<,EX2P&YL^2S4*[J$AB'W/I@:\
M')]@WPP+5#&\[]D*417 K[LC\:<> Z)!'R2*>GAYK;10*4 FV*=/KH]^&F*%
M3(I^T"GPX0!5MK3<P0^+USL,=46N".(?]\E-,V69.B!J-[1.LRT5\D7CF39&
MZ\H676R+PO%]ARV:67-2F(P9LQAU93'&%J,T!3-F"6HKU$!E62C+8K%E4:TT
M%A@60)5<)1M:ODG^BH"(@6!!A6SHE:JR-D['VJA5]!<$;,00+PYB:LQ9$,L1
M<:EJOSI.NO?P\3;K4Y'E D>6FR]$EN=*$[',CQO5T]D5L&:;>@%[$_]P$=??
M6 [_-'_H8EH/6)!EQK\G+D]PI5(5^"(3L>27Y>4*OS13-BJNU1J51JVU]'*U
MHFUYK:&UMWIRU6([E5I[N[>NOE9KU4]ZK>U*0V_F! ?46O>UUEJ[L]9;MZX0
MK%975'Q7\Y7S^>,GR[9!CP!-"RL(82L3'6R=AD5KP6%IYI[6V.Q%&:NBG].U
M.4C1M7H$R"W*:_P>3,T>8&^DWWHWS<36 O/W5M#G'.)_U B?W]FZT&M[1^F"
M U!7 -P"@'_>_@D0[&C-N:XQBD85C1: 1HLOMI>0\$X$=PXT[(4AS3VT.YL%
M2S$[GLWM,M--S[12N[JZT? F9)Z!GGH*R;*(9(WVEET;CX-DFPC5K(JZ)4=1
M_Y[.2XKX\DA\VK9M+16'5TBV+I)5JZL'=V<,R3;L=99'6V?9;)D=C3I8=FZM
M2JN1;5I\/9<"=.H#A_169:_31HYQR"=_IHW*7B<CY_5,YV_-!=_FE<9AJB_0
MB:*UUJKL=7YG7M$ZUV?:K.QU-%M>S[2(@[:P2&66C9V*HWUY:X3O]\D4QB+.
ME=';ZF1L2)_"AB/ZV;3,#FS/J=)[5IN9<JV((2_$4&U5,T8,"AN.B T=-<WV
M@&Q3GV&;RLFKG+QH92N'8-'.M%59G5AQHF>:5WU7J]3.E9M7,*O5\>031>Q<
MGZF*,IZ,!KJ8D:GAE^K.->]4J*+NW VJ%"9\M%9S9N4NS:6#K-;8J[JKL"%7
MV*"W5V=L9\)=FBN%M+&#L@=%"L<@A8YBC H;$FQHJ3C2 >&M2@54%&DV#[E:
MV:MNDE<G7L[/5#EFBZ/K5E6I@!!?'<6JBG:FP*I4$L-I:)]GU4I[\QA28;R]
M4]/=E)F:(S.U6=]KA9K"A1SAPEZ%U0GJMO]0'#&'5,"[%^H7&:,%A0\*'TY%
MF;[Y5' E>G%GSV6C# LM11:#(D]<8_$.ZJ5V.^E_>Q2NE2EVI1#Q6#NHE3H=
MA8@YM"D6'Z>N%SLYI+ADV*A6%1DJ1#SV#FJE6JNA$+%8=M02'71A2DR\"'EK
MC8/C>TRKW8[[4;?FZ=9U:&7J-<4SYI=$Q)8,E<[R8:I;"T@D.4E>=!-ZD8.D
M:4!40N.<\E:M[+6)VQ&V=/)90G5=)33FTD&SK)I<J[147PR>3Z!7]MI7+:^8
MG?,S53F-17,?+,UI;"S/:51N!'5K,2RD;)A%2W("Z#=R3\/OZ920,[&S& Z@
M5&D%=5H? 9HGI,4L0:=JI:[0*5/HE'ES;_'>JY465Y'(R9-44W'HC)%4KM%)
MKW04.F4*G7)MXBY)AJCHRL!5MQ[5P#TA&W<QKP4"_.F'1ON">,Q'%D$'C'BN
MY80["?>I6_-YJZ*8Y13S#V(,J0-D8CF$?3-8$&"D'*\IBCG=6_=',0+7%[RS
M,!1U\XG\]$-3NR".&Y(1HPZLNQ_9:Y#32R#:_ #5J]2KU*LN]L#.LM<.7-UY
MK#L+C"H%WIJZ4Z&*NE.ABKHSRW<J5%%W*E11=RI447<J5%%W9OE.A2KJ3H4J
MZDZ%*NI.A2KJSBS?J5!%W:E01=VI4$7=J5!%W9GE.Q6JJ#L5JJ@[%:JH.Q6J
MJ#NS?*="%77G)JCR<TA[-H/_FM;3K[_ /_$3<\7.KT0URZ^_]/ Q64PR^]2(
M=PB.,^&;TY4R_XV"T.J/7^VX+$9[J3Y:Q[*82QH,R7O;?2;4,<E;:E/'8.1A
MR%BXP6[D7T+7X[_*S'U1-51;O%WQ)\LQ83-OREJ;I_@? 0 X_$MO7NRE$\'L
M"N8JDV %T\#2M$H=(?$X9.32'0&ZCLF .=@YEYGD1[W2(#W+MBW7P7K OL\8
M,? $^WB"ED-"> Y6Y)ODKXCZ@)YXFU[5:^2)^4$4X"O:R2M6/*!77CI^==A[
M.&P^BJYU$<R<"3]!. (+ &CB"<$Q:C4LIR;!D/J,/-. F,RPX6>X[I!N- #(
MBQX76HD_7^(4CC=ZU.(W/3 O9*,>\\5][?B^T"74M@$PKO%UZ-HF8 Y^TV>&
M"VNB_)>I#R1/^LSS60#@PC;/E&C5U]CLV6<T8("L[DA@%E&<Y7C(QAD^8H+E
M/+$@','G -MP,!TRF%J]TDK8 ]YELEY(W"@,0O@-3S6YM5E-,2.!% E"D5I5
MH,2+7&3Y42^5D-\A:A.1S<5[_(BL0X-#L:D7L#?Q#Q>Q>F Y'+;\H8OI#V#3
M]9DJ5_X]<?GBV3+#X9M6HZ)W]->O$A54?EA<U2J(+8F:,G6M4:\T]?;2R]6*
MMN6U5FOY1U<]N6JQFEYIMIMJL?M9;&?MU^9"S3Z"E;>\ECTN147>LWZWHZR5
MN/_X5G#CH,1[1N ^4#E8I\G*R_M?O]YW,R!FKV74'S4BU3"]ID"W+>CT X-N
M8:NR@H#US]L_ :X=K3G7KRX7;#E;K#Y'#'TR8BIQTWS_:-"E-#$+G(R-:]QL
M^OSZN\Q(6\?%V],K[96-*M?>YA9=+!6*G02*U5X8X:)03*'8]\\9T<]7;W$S
M]6V_J)<];4=I4%MBWB7UK)#:Y.J;QQS3@O=^UXC!F<NYYR_Y82' 03(V5UKA
M@L(%A0O'WD&UHJVCO:[3R%YI$$J#F$>P]YACL4/WB^(11W"B['6@I<*%7.'"
M:H>:PH73P86S:J6VC5M"Z0U*;W@1N=[);+V W%'+5'I##OF#]H)MH63%*>'"
M7@?=*US($2XHGX/2'?:*8 \\I_^>>9%O#&F@0A:Y9!,\$TZ_4&)#X8/"!X4/
M"]2(M1)OE!JAU(CM$*P+:\%1J^\L.\+R4:Y6!.1L),L$YGQ?&["-Y-9\C"!?
M#*!&+6O.8 56!=:E\D))B^-*B_@6>2KMK>;%JV'Q:Z'J&J_)'IX<3%/IS,)R
MX8S-%<-[\Z3&W+@A$^/C;R(L+@_(B([Y&%_8 S$CA@T+?#?B]>G?.<]W5^--
M,_<>17.;TMQ&+8!4/P%5HI^SQ:[93T#5U MC656";U2RW/GIAWKKHE;E_U%U
M]!M"3],%^#0!/E5+O\-:^L=WBVKI3\(AF/1^NI[T?MIC0?D)U&'FJ @36WMM
M5^B;P2I?A5I9VENG4E.8I3!K'^GZC4I]:[?W?M'N)#2&=]C^\7;2_E$E(N4P
MT0 [=68L(*>0X6AJ8+O24<B@D$&(5^T%SK#OJ+**K!XWLJJBBRJZ>(SHXCZ&
M;,ACK6,(S7,#*[1<X$',IJ'UQ&3D3)QY^BFYH>KD$=J#U4?A\D<VZ4R>_G?H
M3TAZP,H]G]&O9=J'_;VA]C,=!].?&5E.C*K-5@5W-;N@55!9!V*''T*RJ$_]
MJU^[GSY<W9#[J[O;^\<'\OC;]?T[\L?G[OWCU3UY?WW3O;F\[GZ$ZP^?/SX^
M+-GI@9=\AXF5K45GG8NQ+WR@Q(?(,G'<2Z;'UBP&_WO7YZ-+^I%MDS&C?CRZ
M(C4WQ7&?"?OF,2,,.(-?NDW)H3(V5&+QQ@\Y5&(1ZLP-E:B)$28X%8+X[(DY
MT:1<Z0CPB6?:^-0! N634MIQGGT\K ($.OZU/O77Y9,J%'I\Q\P1@1ZW#J'D
M:#C[ZM</W>X=Z=' "DKDZNXA4_@)0 )>C#BIZ966'--S5&B%]!O!@5-9 I-6
MKU1?(Y2T1J7Q6A%K@8G5<9URI@FV7=&K@F#;E795$>QB@FT"G7*";0'E*H+=
MH_(5-[EE"YK<'@,5X-![C%#/\]UOU@CPTAZ3'SL-J86-E+ZU=XP0#03\^08"
MQT ']*4!2N!((IP;UZBNBP@;F)]+_!R6^<]75K_>:S"CTVCHC4:]5=-[=<-D
M#8W5^JS3;.O5_]-JKS)J_"YF]X]\-N0?<C;DG>^:D1%R*71G>0SO)Y\],R4/
M,NOX28\Y!6Z!';-,8=>[MNT^ V*3B.\DP'F5 ;/!F(<[O-26O7C+\,>!3T<O
MV/I;3A7,RM'?.OBAP3CS"WVDODU#.J(]<M;]](&T&JWSEP@]VT,^CR\ -M#A
MKQUR:X1NC_DE O1#R3/SD43X<%:@(#Z,%0EM8+L]4!WN4$H0G;QC'S]Z0ZM<
MJVJPC<@<<QH+K%%DA]1A;A2 +/>BGFT%0V;&2M]^=\]?^ 8U',M8XT1NV#.Y
M<@8V+OQ?;N0[L#W01S\QTS+@YB-*PA)A3]2.Q$2G,"$0,"!(W_(#1.>R8=,@
MD+-9K0'%@ 2LWV0 _K)M?64$B !W5B-G[SY^K)WC>P:,O_&M]7BUC]VU*EIC
M+4R<B[D@09=KE?:"HB:P[3C;1@K26O7C$1 H*&<]*_"88?4M@SR6#6:#*NT,
MZ(#YYV3D@LR);%9"7/=@6WQ>[K,5#@DUG]![;@*"8C @&.'09/ZT'<%Q&'C1
M)V</EQ\OS\GST"5#"H1'+9R>&SZ[Q/7A[9PJ+?@1U\6'Z(8^HSPUNT+^S3]#
M1H"ZU)$RL1QYW+RJ5IKPN!,. S1 874ACEUVD8N6^2O@K]0>@P4-) J_68YA
M1RA>M6IULA&X@ 2<2%:M2D8#8KHXKQE=[!,N;C+X6A"*0>3P0;?W7W@$3AG4
MS,"#2XR;H.3L]OX>1'#G O<%C'T,L#0]%]9WCNNN5U^3LTX+;4/#=?K8(M-@
M?/4^T(8(Q.J=<D,_KQ#0#G"T-?[CN,0!N@YHGX5CX$<#V!M JP='_L0P7@DZ
M!(Z^!CT3]R/8F61A.9]DGBNY\PYE32)<%D@3.,L>0VX51+V1%8:3,_M<>:B0
M]ZYK<I'SSH\&I&N.+,?B2(=^^[/W[[I(298QQ&'DL!<01J#S<8GV%J.IX=!W
MH\&08P[UQK  CBJA]/JGT+DO T@)M2%R4A/$W R5PW$S)P \EV2.Y"RNF%;
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MB96 IBR;FLP&GDK!9 %+W W<$2L[;,!]<B ?A^7S$GDK_%P>V-&1'Z#-:D1
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M3C "%"Z?#87'-#XC>7ZYC4T=)K5O\>%?PI]P:>0.'1R6P7C5!A,.*R#HV82
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MG&5V:^4#Y5R%0ZU-Z]046A]0:1.*&@@Q;E],ZVK<.DF'QN4!+= R1.)YHF"
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MC,!U1[;!(V/X00X@FMK.;+(_$(?!_+A(&N=P 2);\)%4C^?5<"RL&+MG6*Q
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ME"=1#$&H@C;F#RW>WRK"/(*X*S0-L  :??[!(IQ1IYB54V1X=*XWM&PX2A;
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MM8'L,_ Q6*L;^8:4,ND7QK@5&T=B[#M6QXF<R1$*&$F^O".UQ)F7M 5KHM+
M*TNB9[681 N<%S[<1X<)9H]$'!=]?E?R"MC78CH$SB12>W+)BY=T?>]A@X;N
M",SX3*]^B3&'ZY9R=V2%4MF('$"]KW&!2=(%FL^,LD2R/#+1)%,HB/JR"S27
MR+@6['U@V3;BM>"1?,C($[\KT:+XSX :$<ZOG.B3)N-=GP4E.: 2<70>1B/J
MR$;IW$D2R"[L7&]">=]#39)_#"D*B<BU S$:(9D7*]Z"/A=\@]BL3V$UT@&+
MHPV^67'P*MU">B)OI/1P3,H%I<UO%2^6X'FY+4=F<:'O&IQ[HFKI,RKV!G?!
M_K$8:"2GYSI,3D^W,:('BF/ V2.O6 L!:KQB,_3QX!!5N">&RS:AIH@B-C)D
MU,;)$W$U.#]]4'UI*$O/XAL]YL+!_$_ ^X'#P7<1TB$SAHY 1P_>S4# B6[-
M6J==+0F:Y+HL3DGE&DP/F*Z3,%[>=PW?R:@IC0R&VB6JP-.O%ZY["PT ?)^/
MZB7L'\[ MJ2<GU3Q^6!$FI,/Q(W_)SB/G=4MCX?Q^"219"(Y9X3<TT2?Z7A"
M>#E&)]XA,H%XK3H!I< $_-7G^()UE&!>_(O;4]?"WD.FTQ7X%8.1AV>P$TC\
MSAL:F/2OLE:M\@/\QBUR-"YB#,!\10=(U8Q7PM.LJA>R'"C1?C[P,D=0M?[M
M^E]Y=63 []0ND*7<@'* 992E%]YRB3$U$)$? :F 7Z3>\/FA2QY=DXZE,9]
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M;59H ?B%YI#,^1OS[4DW@@"$X"9)X%D>M%#9Q$&G=C65; PO1M0=I)HIBX7
MGV/V(RIU9DC%?>&#HM#<]9*<!>!3F!=E8]JLG93T@$[F\@ VQD<GV0?\3KD
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M<LP25W4DJ4[PFI_C*C)[9@DU\"X!?* Q'U!,) \3$XLVBF)@*G:2F;@D$B$
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M0:)#NZ37.WM'A^*I/K<\7RXN&5^JB.L+][@0N3.'&[5&(V-\HA!@K6L*K'L
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MU\"JV\]BUX/!FI;)!MZP!<+=8-B3\B#2O?T2(<C9D%[(1CWFDUJUM!]?9Q[
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M4,+B4 V E*183U+LN+N40J&3ITG5\O9PO9T41%7+VSQFO9.S7C'+J)3*O%N
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M+FAT;5!+ 0(4 Q0    ( .@Y7U>E5R075@,   L,   1              "
M 2(9  !A;6=N+3(P,C,Q,#,Q+GAS9%!+ 0(4 Q0    ( .@Y7U=N[*Z5%PD
M &!#   5              "  :<<  !A;6=N+3(P,C,Q,#,Q7V1E9BYX;6Q0
M2P$"% ,4    " #H.5]7AQR2"18.   '@P  %0              @ 'Q)0
M86UG;BTR,#(S,3 S,5]L86(N>&UL4$L! A0#%     @ Z#E?5[=1UK"Q"
MOT0  !4              ( !.C0  &%M9VXM,C R,S$P,S%?<')E+GAM;%!+
M 0(4 Q0    ( .@Y7U<\3+O;@WL  $29"  ?              "  1X]  !A
M;6=N+3(P,C,Y,S!E87)N:6YG<W)E;&5A<V4N:'1M4$L%!@     &  8 E $
' -ZX      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
